Axsome’s Wait Pays Off With Broad Auvelity Label For Major Depression
Executive Summary
After a year-long delay, Axsome gets US FDA approval of bupropion/dextromethorphan combo with broad label for major depression. Firm expects to launch in Q4 with pricing intended for broad patient access.
You may also be interested in...
Axsome Succeeds In Narcolepsy Phase III, But Is That Enough?
Analysts say reboxetine looks approvable for cataplexy related to narcolepsy, but debate how broadly the drug may be adopted in a generic-laden therapeutic space.
Zuranolone Launch Requires Sage To Shift The Way Doctors Treat Depression
CEO Barry Greene and team spoke with Scrip about Sage and Biogen’s focus on short-term, episodic dosing, and said doctors and payers – pending zuranolone’s approval – are responding to the sales pitch.
AbbVie’s Blockbuster Vraylar Adds Significant Indication, Adjunctive MDD
Already selling at a run rate above $2bn annually, AbbVie predicts the atypical antipsychotic could reach the $4bn mark with a new US indication for adjunctive treatment of major depressive disorder.